| 000 | 01462 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516065415.0 | ||
| 264 | 0 | _c20120409 | |
| 008 | 201204s 0 0 eng d | ||
| 022 | _a1532-1924 | ||
| 024 | 7 |
_a10.1016/j.beha.2011.09.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRowe, Jacob M | |
| 245 | 0 | 0 |
_aEvaluation of prognostic factors in AML. Preface. _h[electronic resource] |
| 260 |
_bBest practice & research. Clinical haematology _cDec 2011 |
||
| 300 |
_a485-8 p. _bdigital |
||
| 500 | _aPublication Type: Congress; Editorial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAminoglycosides _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCCAAT-Enhancer-Binding Proteins _xgenetics |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDNA (Cytosine-5-)-Methyltransferases _xgenetics |
| 650 | 0 | 4 | _aDNA Methyltransferase 3A |
| 650 | 0 | 4 |
_aEurope _xepidemiology |
| 650 | 0 | 4 | _aGemtuzumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdiagnosis |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 773 | 0 |
_tBest practice & research. Clinical haematology _gvol. 24 _gno. 4 _gp. 485-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.beha.2011.09.003 _zAvailable from publisher's website |
| 999 |
_c21353109 _d21353109 |
||